Smartwatch AI could spot dangerous thyroid Flare-Ups
NCT ID NCT07017907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a software called Glandy HYPER that uses artificial intelligence to detect thyrotoxicosis—a dangerous overactive thyroid state—in people with Graves' disease. The AI analyzes resting heart rate data from wearable devices like smartwatches and compares it with standard blood tests. Researchers will enroll 15 adults with Graves' disease to see how well the software performs, but its results will not be shared with participants or affect their medical care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Heart rate-based AI software for detecting thyrotoxicosis
What this could lead to
If successful, this AI tool could offer a non-invasive way to monitor thyroid storms using wearable devices, potentially improving early detection.
What could go wrong
This is a small, early-stage study with only 15 participants, so results may not apply broadly. The software is not FDA-approved and is for research only.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Umesh Masharani
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••